Detail akcie Arcutis Biother Rg online

Business Summary: Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Arcutis Biotherapeutics Inc revenues increased 97% to $246.6M. Net loss decreased 74% to $33.5M. Revenues reflect Product revenue, net increase from $97.2M to $244.6M. Lower net loss reflects Treatments for dermatological diseases segment loss decrease of 75% to $30.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.08 to -$0.27.